Early experience with novel immunomodulators for cancer treatment

Bibliography

• EHRLICH P: Über den jetzigen stand der karzinomforschung [Article in German]. Ned. Tijdschr. Geneeskd. (1909) 5:273-290.
   Google Scholar
• MCKECHNIE A, ROBINS RA, EREMIN O: Vaccination and malignant disease: promising therapeutic approach. Surgeon (2005) 3:224-233.
   PubMed Web of Science ®Google Scholar
• BOON T, VAN BAREN N: Immune surveillance against cancer and immunotherapy synergy or antagonism. N. Engl. J. Med. (2003) 348:252-254.
   PubMed Web of Science ®Google Scholar
• MCKECHNIE A, ROBINS RA, EREMIN O: Immunological aspects of head and neck cancer: biology, pathophysiology and therapeutic mechanisms. Surgeon (2004) 2:187-207
   PubMed Web of Science ®Google Scholar
• DUNN GP, OLD LJ, SCHREIBER RD: The immunobiology of cancer immunosurveillance and immunoediting. Immunity (2004) 21:137-148.
   PubMed Web of Science ®Google Scholar
• MITCHELL MS: Biomodulators in cancer treatment. J. Clin. Pharmacol. (1992) 32:2-9.
   PubMed Web of Science ®Google Scholar
• COLEY-NAUTS H, FOWLER GA, BOGATKO FH: A review of the influence of bacterial infection and bacterial products (Coley's toxins) on malignant tumours in man. Acta Medica Scand. (1953) 145:5-97.
   Google Scholar
• COLEY WB: Further observations upon the treatment of malignant tumors with the toxins of erysipelas and Bacillus prodigiosus with a report of 160 cases. Johns Hopkins Hosp. Bull. (1896) 7:175.
   Google Scholar
• PAREKH DJ, BOCHNER BH, DALBAGNI G: Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments. J. Clin. Oncol. (2006) 24:5519-5527.
   PubMed Web of Science ®Google Scholar
• BETTEX-GALLAND M, STUDER UE, WALZ A, DEWALD B, BAGGIOLINI M: Neutrophil-activating peptide-1/interleukin-8 detection in human urine during acute bladder inflammation caused by transurethral resection of superficial cancer and bacillus Calmette-Guerin administration. Eur. Urol. (1991) 19:171-175.
   PubMedGoogle Scholar
• ROSENBERG SA, YANG JC, WHITE DE, STEINBERG SM: Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann. Surg. (1998) 228:307-319.
   PubMed Web of Science ®Google Scholar
• Biological Response Modifiers: Subcommittee Report. Mihich E, Fefer A (Eds), National Cancer Institute Monograph 63. Bethesda, MD, USA (1983). NIH publication 83-2606.
   Google Scholar
• FAUCI AS, ROSENBERG SA, SHERWIN SA, DINARELLO CA, LONGO DL, LANE HC: NIH conference. Immunomodulators in clinical medicine. Ann. Intern. Med. (1987) 106:421-433.
   PubMed Web of Science ®Google Scholar
• MOTZER RJ, HUTSON TE, TOMCZAK P et al.: Sunitinib versus interferon-α in metastatic renal-cell carcinoma. N. Engl. J. Med. (2007) 356:115-124.
   PubMed Web of Science ®Google Scholar
• JACK A, BOYES C, AYDIN N, ALAM K, WALLACK M: The treatment of melanoma with an emphasis on immunotherapeutic strategies. Surg. Oncol. (2006) 15:13-24.
   PubMed Web of Science ®Google Scholar
• BORDEN EC: Gene regulation and clinical roles for interferons in neoplastic diseases. Oncologist (1998) 3:198-203.
   PubMedGoogle Scholar
• VAN HORSSEN R, TEN HAGEN TL, EGGERMONT AM: TNF-α in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist (2006) 11:397-408.
   PubMed Web of Science ®Google Scholar
• TAGUCHI T, MITCHAM JL, DOWER SK, SIMS JE, TESTA JR: Chromosomal localization of TIL, a gene encoding a protein related to the Drosophila transmembrane receptor Toll, to human chromosome 4p14. Genomics (1996) 32:486-488.
   PubMed Web of Science ®Google Scholar
• BEUTLER B, HOEBE K, DU X, ULEVITCH RJ: How we detect microbes and respond to them: the Toll-like receptors and their transducers. J. Leukoc. Biol. (2003) 74:479-485.
   PubMed Web of Science ®Google Scholar
• LEMAITRE B, NICOLAS E, MICHAUT L, REICHHART JM, HOFFMANN JA: The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell (1996) 86:973-983.
   PubMed Web of Science ®Google Scholar
• BELVIN MP, ANDERSON KV: A conserved signaling pathway: the Drosophila Toll–dorsal pathway. Ann. Rev. Cell Dev. Biol. (1996) 12:393-416.
   PubMed Web of Science ®Google Scholar
• KILLEEN SD, WANG JH, ANDREWS EJ, REDMOND HP: Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword? Br. J. Cancer (2006) 95:247-252.
   PubMed Web of Science ®Google Scholar
• MCGETTRICK AF, O'NEILL LA: The expanding family of MyD88-like adapters in TLR signal transduction. Mol. Immunol. (2004) 41:577-582.
   PubMed Web of Science ®Google Scholar
• HUANG B, ZHAO J, LI H et al.: Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. (2005) 65:5009-5014.
   PubMed Web of Science ®Google Scholar
• WILSON HL, DAR A, NAPPER SK, LOPEZ AM, BABIUK LA, MUTWIRI GK: Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides. Int. Rev. Immunol. (2006) 25:183-213.
   PubMed Web of Science ®Google Scholar
• AKIRA S, UEMATSU S, TAKEUCHI O: Pathogen recognition and innate immunity. Cell (2006) 124:783-801.
   PubMed Web of Science ®Google Scholar
• KRIEG AM: Therapeutic potential of toll-like receptor 9 activation. Nat. Rev. Drug Discov. (2006) 5:471-484.
   PubMed Web of Science ®Google Scholar
• KREIG AM: Development of TLR9 agonists for cancer therapy. J. Clin. Invest. (2007) 117:1184-1194.
   PubMed Web of Science ®Google Scholar
• LINK BK, BALLAS ZK, WEISDORF D et al.: Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J. Immunother. (2006) 29:558-568.
   PubMed Web of Science ®Google Scholar
• PASHENKOV M, GOESS G, WAGNER C et al.: Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J. Clin. Oncol. (2006) 24:5716-5724.
   PubMed Web of Science ®Google Scholar
• SPEISER DE, LIENARD D, RUFER N et al.: Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. (2005) 115:739-746.
   PubMed Web of Science ®Google Scholar
• Leichman G, Gravenor D, Woytowitz D et al.: CPG 7909, a TLR9 agonist, added to first line taxane/platinum for advanced non-small cell lung cancer, a randomized, controlled Phase II study. J. Clin. Oncol. (2005) 23(Suppl.):S630 (Abstract 7039).
   PubMed Web of Science ®Google Scholar
• DROEMANN D, ALBRECHT D, GERDES J et al.: Human lung cancer cells express functionally active Toll-like receptor 9. Respir. Res. (2005) 6:1.
   PubMed Web of Science ®Google Scholar
• WANG H, RAYBURN ER, WANG W, KANDIMALLA ER, AGRAWAL S, ZHANG R: Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9. Mol. Cancer Ther. (2006) 5:1585-1592.
   PubMed Web of Science ®Google Scholar
• CARPENTIER A, LAIGLE-DONADEY F, ZOHAR S et al.: Phase I trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro Oncol. (2006) 8:60-66.
   PubMed Web of Science ®Google Scholar
• DAMIANO V, CAPUTO R, BIANCO R et al.: Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors. Clin. Cancer Res. (2006) 12:577-583.
   PubMed Web of Science ®Google Scholar
• RAYBURN ER, WANG W, ZHANG Z, LI M, ZHANG R, WANG H: Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy. Prostate (2006) 66:1653-1663.
   PubMed Web of Science ®Google Scholar
• WANG H, RAYBURN ER, WANG W, KANDIMALLA ER, AGRAWAL S, ZHANG R: Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy. Mol. Cancer Ther. (2006) 5:2106-2114.
   PubMed Web of Science ®Google Scholar
• MASON KA, ARIGA H, NEAL R et al.: Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin. Cancer Res. (2005) 11:361-369.
   PubMed Web of Science ®Google Scholar
• MENG Y, CARPENTIER AF, CHEN L et al.: Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int. J. Cancer. (2005) 116:992-997.
   PubMed Web of Science ®Google Scholar
• MILAS L, MASON KA, ARIGA H et al.: CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res. (2004) 64:5074-5077.
   PubMed Web of Science ®Google Scholar
• RHEE SH, HWANG D: Murine TOLL-like receptor 4 confers lipopolysaccharide responsiveness as determined by activation of NF-κB and expression of the inducible cyclooxygenase. J. Biol. Chem. (2000) 275:34035-34040.
   PubMed Web of Science ®Google Scholar
• CHICOINE MR, ZAHNER M, WON EK et al.: The in vivo antitumoral effects of lipopolysaccharide against glioblastoma multiforme are mediated in part by Toll-like receptor 4. Neurosurgery (2007) 60:372-380.
   PubMed Web of Science ®Google Scholar
• GERSTER JF, LINDSTROM KJ, MILLER RL et al.: Synthesis and structure-activity-relationships of 1H-imidazo[4,5-c] quinolines that induce interferon production. J. Med. Chem. (2005) 48:3481-3491.
   PubMed Web of Science ®Google Scholar
• MILLER RL, IMBERTSON LM, REITER MJ, GERSTER JF: Treatment of primary herpes simplex virus infection in guinea pigs by imiquimod. Antivir. Res. (1999) 44:31-42.
   PubMed Web of Science ®Google Scholar
• SMITH KJ, HAMZA S, SKELTON H: The imidazoquinolines and their place in the therapy of cutaneous disease. Expert Opin. Pharmacother. (2003) 4(7):1105-1119.
   PubMed Web of Science ®Google Scholar
• JURK M, HEIL F, VOLLMER J et al.: Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat. Immunol. (2002) 3:499.
   PubMed Web of Science ®Google Scholar
• DUMMER R, UROSEVIC M, KEMPF W, HOEK K, HAFNER J, BURG G: Imiquimod in basal cell carcinoma: how does it work? Br. J. Dermatol. (2003) 149(Suppl. 66):57-58.
   PubMed Web of Science ®Google Scholar
• SCHÖN MP, SCHÖN M: Immune modulation and apoptosis induction: two sides of the antitumoral activity of Imiquimod. Apoptosis (2004) 9:291-298.
   PubMed Web of Science ®Google Scholar
• SCHULZE HJ, CRIBIER B, REQUENA L et al.: Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled Phase III study in Europe. Br. J. Dermatol. (2005) 152:939-947.
   PubMed Web of Science ®Google Scholar
• CRAFT N, BRUHN KW, NGUYEN BD et al.: The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine. J. Immunol. (2005) 175:1983-1990.
   PubMed Web of Science ®Google Scholar
• BERNHARDT SL, BUANES TA, MØLLER M, ERIKSEN JA, GEUDERNACK G: Imiquimod a new adjuvant for telomerase peptide vaccine: a Phase I trial in patients with inoperable pancreatic cancer. ASCO Annual Meeting 2005 Proceedings. J. Clin. Oncol. (2005) 23(16S):9623.
   Google Scholar
• DUDEK AZ, YUNIS C, KUMAR S, HARRISON LI, HAWKINSON RW, MILLER JS: Immune response activation by a Toll-like receptor 7 agonist: results of a Phase I study. ASCO Annual Meeting Proceedings. J. Clin. Oncol. (2005) 23(16S):2515.
   Google Scholar
• KNIGHT R: IMiDs: a novel class of immunomodulators. Semin. Oncol. (2005) 32(Suppl. 5):S23-S30.
   PubMed Web of Science ®Google Scholar
• SAMPAIO EP, SARNO EN, GALILLY R, COHN ZA, KAPLAN G: Thalidomide selectively inhibits TNF-α production by stimulated human monocytes. J. Exp. Med. (1991) 173:699-703.
   PubMed Web of Science ®Google Scholar
• MOREIRA AL, SAMPAIO EP, ZMUIDZINAS A, FRINDT P, SMITH KA, KAPLAN G: Thalidomide exerts its inhibitory action on TNF-α by enhancing mRNA degradation. J. Exp. Med. (1993) 177:1675-1680.
   PubMed Web of Science ®Google Scholar
• NOGUEIRA AC, NEUBERT R, HELGE H, NEUBERT D: Thalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells. Life Sci. (1994) 55:77-92.
   PubMed Web of Science ®Google Scholar
• LEBLANC R, HIDESHIMA T, CATLEY LP et al.: Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood (2004) 103:1787-1790.
   PubMed Web of Science ®Google Scholar
• BARTLETT JB, DREDGE K, DALGLEISH AG: The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat. Rev. Cancer (2004) 4:314-322.
   PubMed Web of Science ®Google Scholar
• CORRAL LG, HASLETT PA, MULLER GW et al.: Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J. Immunol. (1999) 163:380-386.
   PubMed Web of Science ®Google Scholar
• STIRLING D: Thalidomide: a novel template for anticancer drugs. Semin. Oncol. (2001) 28:602-606.
   PubMed Web of Science ®Google Scholar
• D'AMATO RJ, LOUGHNAN MS, FLYNN E, FOLKMAN J: Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA (1994) 91:4082-4085.
   PubMed Web of Science ®Google Scholar
• DREDGE K, MARRIOTT JB, MACDONALD CD et al.: Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br. J. Cancer (2002) 87:1166-1172.
   PubMed Web of Science ®Google Scholar
• GUPTA D, TREON SP, SHIMA Y et al.: Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia (2001) 15:1950-1961.
   PubMed Web of Science ®Google Scholar
• GANDHI AK, NAZIRUDDIN S, VERHELLE D, BRADY H, SCHAFER P, STIRLING D: Anti-proliferative activity of CC-5013 in 5q-myelodysplastic syndrome (MDS) and acute lymphocytic leukemia (ALL) cell lines. ASCO Annual Meeting Proceedings. J. Clin. Oncol. (2004) 22(Suppl. 14):6618.
   Google Scholar
• MITSIADES N, MITSIADES CS, POULAKI V et al.: Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood (2002) 99:4525-4530.
   PubMed Web of Science ®Google Scholar
• HAROUSSEAU JL: Thalidomide in multiple myeloma: past, present and future. Future Oncol. (2006) 2:577-589.
   PubMedGoogle Scholar
• RAJKUMAR SV, BLOOD E, VESOLE D, FONSECA R, GREIPP PR; Eastern Cooperative Oncology Group: Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol. (2006) 24:431-436.
   PubMed Web of Science ®Google Scholar
• AMATO RJ, MORGAN M, RAWAT A: Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma. Cancer (2006) 106:1498-1506.
   PubMed Web of Science ®Google Scholar
• FINE HA, FIGG WD, JAECKLE K et al.: Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J. Clin. Oncol. (2000) 18:708-715.
   PubMed Web of Science ®Google Scholar
• FINE HA, WEN PY, MAHER EA et al.: Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J. Clin. Oncol. (2003) 21:2299-304.
   PubMed Web of Science ®Google Scholar
• REIRIZ AB, RICHTER MF, FERNANDES S et al.: Phase II study of thalidomide in patients with metastatic malignant melanoma. Melanoma Res. (2004) 14:527-531.
   PubMed Web of Science ®Google Scholar
• HWU WJ, KROWN SE, MENELL JH et al.: Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J. Clin Oncol. (2003) 21:3351-3356.
   PubMed Web of Science ®Google Scholar
• LABER DA, OKEKE RI, ARCE-LARA C et al.: A Phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma. J. Cancer Res. Clin. Oncol. (2006) 132:611-616.
   PubMed Web of Science ®Google Scholar
• GORDINIER ME, DIZON DS, WEITZEN S, DISILVESTRO PA, MOORE RG, GRANAI CO: Oral thalidomide as palliative chemotherapy in women with advanced ovarian cancer. J. Palliat. Med. (2007) 10:61-66.
   PubMed Web of Science ®Google Scholar
• MORABITO A, CARILLIO G, LONGO R, GASPARINI G: Thalidomide is inactive in heavily pretreated patients with metastatic breast cancer. Cancer J. (2005) 11:248-251.
   PubMed Web of Science ®Google Scholar
• DAL LAGO L, RICHTER MF, CANCELA AI et al.: Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer. Invest. New Drugs (2003) 21:359-366.
   PubMed Web of Science ®Google Scholar
• SHARMA RA, STEWARD WP, DAINES CA, KNIGHT RD, O'BYRNE KJ, DALGLEISH AG: Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: Phase I clinical trial of three dosing schedules in patients with solid malignancies. Eur. J. Cancer (2006) 42:2318-2325.
   PubMed Web of Science ®Google Scholar
• ZHANG MM, CHAN JK, HUSAIN A, GUO HY, TENG NN: Safety and efficacy of lenalidomide (Revlimid®) in recurrent ovarian and primary peritoneal carcinoma. Gynecol. Oncol. (2007) 105:194-198.
   PubMed Web of Science ®Google Scholar
• BARTLETT JB, MICHAEL A, CLARKE IA et al.: Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br. J. Cancer (2004) 90:955-961.
   PubMed Web of Science ®Google Scholar
• CHOUEIRI TK, DREICER R, RINI BI et al.: Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer (2006) 107:2609-2616.
   PubMed Web of Science ®Google Scholar
• KALMADI S, DAVIS M, DOWLATI A et al.: Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid®) in patients with advanced solid tumors. Invest. New Drugs (2007) 25:211-216.
   PubMed Web of Science ®Google Scholar
• VAN DER STRATE BWA, BELJAARS L, MOLEMA G, HARMSEN MC, MEIJER DKF: Antiviral activities of lactoferrin. Antivir. Res. (2001) 52:225-239.
   PubMed Web of Science ®Google Scholar
• TSUDA H, OHSHIMA Y, NOMOTO H et al.: Cancer prevention by natural compounds. Drug Metab. Pharmacokinet. (2004) 19:245-263.
   PubMedGoogle Scholar
• TAKAKURA N, WAKABAYASHI H, YAMAUCHI K, TAKASE M: Influences of orally administered lactoferrin on IFN-γ and IL-10 production by intestinal intraepithelial lymphocytes and mesenteric lymph-node cells. Biochem. Cell Biol. (2006) 84:363-368.
   PubMed Web of Science ®Google Scholar
• KUHARA T, YAMAUCHI K, TAMURA Y, OKAMURA H: Oral administration of lactoferrin increases NK cell activity in mice via increased production of IL-18 and type I IFN in the small intestine. J. Interfer.Cytokine Res. (2006) 26:489-499.
   PubMed Web of Science ®Google Scholar
• VARADHACHARY A, SPADARO M, ENGELMAYER J: Talactoferrin alfa is an anti-cancer agent with activity in renal cell cancer (RCC) patients and a novel immunomodulatory mechanism of action. ASCO Annual Meeting Proceedings. J. Clin. Oncol. (2006) 24(Suppl. 18):14648.
   Google Scholar
• HAYES TG, VARADHACHARY GR, FALCHOOK G, SMITH D, VARADHACHARY A, DHINGRA HM: Oral recombinant human lactoferrin (rhLF) slows tumor growth in metastatic NSCLC and other advanced incurable cancers: results of a Phase II study. ASCO Annual Meeting Proceedings. J. Clin. Oncol. (2004) 22(14S):3140.
   Google Scholar
• WANG Y, RAGHUNADHARAO D, RAMAN G et al.: Adding oral talactoferrin to first-line NSCLC chemotherapy safely enhanced efficacy in a randomized trial. ASCO Annual Meeting Proceedings. J. Clin. Oncol. (2006) 24(18S):7095.
   Google Scholar
• BAGULEY BC: Antivascular therapy of cancer: DMXAA. Lancet Oncol. (2003) 4:141-148.
   PubMed Web of Science ®Google Scholar
• BAGULEY BC, CHING LM: Immunomodulatory actions of xanthenone anticancer agents. Biodrugs (1997) 8:119-127.
   PubMed Web of Science ®Google Scholar
• JASSAR AS, SUZUKI E, KAPOOR V et al.: Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. Cancer Res. (2005) 65:11752-11761.
   PubMed Web of Science ®Google Scholar
• RUSTIN GJ, BRADLEY C, GALBRAITH S et al.: Phase I/II Trials Committee of Cancer Research UK. 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: Phase I clinical and pharmacokinetic study. Br. J. Cancer (2003) 88:1160-1167.
   PubMed Web of Science ®Google Scholar
• JAMESON MB, THOMPSON PI, BAGULEY BC et al.: Phase I/II Trials Committee of Cancer Research UK. Clinical aspects of a Phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br. J. Cancer (2003) 88:1844-1850.
   PubMed Web of Science ®Google Scholar
• VON PAWEL J, RECK M, MCKEAGE M; AS1404–201 Study Group Investigators: Update on survival in a Phase Ib/II study of DMXAA combined with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC). Eur. J. Cancer Suppl. (2006) 4:12-16.
   Google Scholar
• JAMESON MB; AS1404–202 STUDY GROUP INVESTIGATORS: Phase II study of DMXAA combined with carboplatin and paclitaxel in recurrent ovarian cancer. Int. J. Gynecol. Cancer (2006) 16(S2):589-598.
   Google Scholar
• ROSENTHAL M, PILI R; AS1404-203 STUDY GROUP INVESTIGATORS: Randomized Phase II study of docetaxel with or without DMXAA (AS1404) in hormone-refractory metastatic prostate cancer (HRMPC). J. Clin. Oncol. (2007) 25:S18-S5115.
   Google Scholar
• BALLAS ZK, KRIEG AM, WARREN T et al.: Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J. Immunol. (2001) 167:4878-4886.
   PubMed Web of Science ®Google Scholar
• OCHSENBEIN AF: Immunological ignorance of solid tumors. Springer Semin. Immunopathol. (2005) 27:19-35.
   PubMed Web of Science ®Google Scholar
• VITALE M, PELUSI G, TARONI B et al.: HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clin. Cancer Res. (2005) 11:67-72.
   PubMed Web of Science ®Google Scholar
• SALIH HR, RAMMENSEE HG, STEINLE A: Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J. Immunol. (2002) 169:4098-4102.
   PubMed Web of Science ®Google Scholar
• HELLEBREKERS DM, CASTERMANS K, VIRE E et al.: Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res. (2006) 66:10770-10777.
   PubMed Web of Science ®Google Scholar
• FRUMENTO G, PIAZZA T, DI CARLO E, FERRINI S: Targeting tumor-related immunosuppression for cancer immunotherapy. Endocr. Metab. Immune. Disord. Drug Targets (2006) 6:233-237.
   PubMedGoogle Scholar
• ROSENBERG SA, YANG JC, RESTIFO NP: Cancer immunotherapy: moving beyond current vaccines. Nat. Med. (2004) 10:909-915.
   PubMed Web of Science ®Google Scholar
• GATTINONI L, POWELL DJ Jr, ROSENBERG SA, RESTIFO NP: Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. (2006) 6:383-393.
   PubMed Web of Science ®Google Scholar
• MARCUS R, HAGENBEEK A: The therapeutic use of rituximab in non-Hodgkin's lymphoma. Eur. J. Haematol. Suppl. (2007) 67:5-14.
   PubMedGoogle Scholar
• PLOSKER GL, KEAM SJ: Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer. Drugs (2006) 66:449-475.
   PubMed Web of Science ®Google Scholar
• LAKE RA, ROBINSON BWS: Immunotherapy and chemotherapy – a practical partnership. Nat. Rev. Cancer (2005) 5:397-405.
   PubMed Web of Science ®Google Scholar
• DEMARIA S, BHARDWAJ N, MCBRIDE WH, FORMENTI SC: Combining radiotherapy and immunotherapy: a revived partnership. Int. J. Radiat. Oncol. Biol. Phys. (2005) 63:655-666.
   PubMed Web of Science ®Google Scholar
• TERANDO A, MULE JJ: On combining antineoplastic drugs with tumour vaccines. Cancer Immunol. Immunother. (2003) 52:680-685.
   PubMed Web of Science ®Google Scholar